Literature DB >> 22370804

[The etiology and management of gout].

B Pazár Maldonado1, A So.   

Abstract

Gout is an inflammatory arthritis caused by monosodium urate (MSU) crystal deposits in and around the joint. The formation of urinary calculi can also occur in gout, but are less common than arthritis. Gout usually presents with recurrent episodes of joint inflammation, which over time lead to tophus formation and joint destruction. In the last decade, significant advances have been made regarding not only the epidemiology and genetics of gout and hyperuricemia but also the mechanisms of inflammation and treatment of gout. In addition, knowledge concerning the key role of interleukin 1 (IL-1) has provided new therapeutic perspectives. However, the current management of gout is often suboptimal, with many Patienten either not receiving adequate treatment or being unable to tolerate existing treatments. New therapeutic agents provide interesting new options for Patienten with difficult-to-treat gouty arthritis.The English full-text version of this is available at SpringerLink (under "Supplemental").

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22370804     DOI: 10.1007/s00393-012-0961-4

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  29 in total

1.  Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.

Authors:  Lisa K Stamp; John L O'Donnell; Mei Zhang; Jill James; Christopher Frampton; Murray L Barclay; Peter T Chapman
Journal:  Arthritis Rheum       Date:  2011-02

2.  Advances in the proper use of colchicine and adapting dosages in other countries: comment on the article by Terkeltaub et al.

Authors:  Frédéric Lioté
Journal:  Arthritis Rheum       Date:  2010-10

Review 3.  New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.

Authors:  Naomi Schlesinger
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

Review 4.  Mechanisms of uric acid crystal-mediated autoinflammation.

Authors:  Fabio Martinon
Journal:  Immunol Rev       Date:  2010-01       Impact factor: 12.988

5.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

6.  Imaging of tophaceous gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography.

Authors:  J C Gerster; M Landry; L Dufresne; J Y Meuwly
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

7.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Authors:  Michael A Becker; H Ralph Schumacher; Luis R Espinoza; Alvin F Wells; Patricia MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

8.  Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events.

Authors:  Corinne Schiltz; F Lioté; F Prudhommeaux; A Meunier; R Champy; J Callebert; T Bardin
Journal:  Arthritis Rheum       Date:  2002-06

9.  Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Authors:  John S Sundy; Michael A Becker; Herbert S B Baraf; Andre Barkhuizen; Larry W Moreland; William Huang; Royce W Waltrip; Allan N Maroli; Zeb Horowitz
Journal:  Arthritis Rheum       Date:  2008-09

10.  Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial.

Authors:  Chi Yin Man; Ian T F Cheung; Peter A Cameron; Timothy H Rainer
Journal:  Ann Emerg Med       Date:  2007-02-05       Impact factor: 5.721

View more
  2 in total

Review 1.  Treatment Options for Gout.

Authors:  Bettina Engel; Johannes Just; Markus Bleckwenn; Klaus Weckbecker
Journal:  Dtsch Arztebl Int       Date:  2017-03-31       Impact factor: 5.594

2.  [Renal diseases in rheumatology].

Authors:  M Janneck; J Velden; C Iking-Konert
Journal:  Z Rheumatol       Date:  2013-08       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.